$22.68 Bn Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market ...
The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
Nature1 年
From IFN to TNF: a journey into realms of lore
The success of infliximab paved the way for the introduction of other drugs with a similar mechanism of action. Three other TNF-blocking agents (etanercept, adalimumab and certolizumab pegol) are ...
来自MSN1 个月
Vedolizumab Edges Out Infliximab for Ulcerative Colitis in Real-World Study
ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...
Nature4 个月
Anti-MCV antibodies—a promising new biomarker for RA
“Anti-MCV antibodies might, therefore, be useful in monitoring response to infliximab therapy...” After adjustment of the anti-MCV assay to produce the same specificity as the anti-CCP assay ...
Medpage Today on MSN5 个月
Should Intensified Infliximab for Refractory Acute Severe UC Be Nixed?
Intensified or accelerated dosing regimens with infliximab (Remicade) did not improve outcomes compared with the standard ...
Medscape13 天
Unsustainable Biosimilar Market Leaves Practices, Patients at a Loss
The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.